Subtopic Deep Dive
Prostaglandin E2 in Cancer Progression
Research Guide
What is Prostaglandin E2 in Cancer Progression?
Prostaglandin E2 (PGE2), produced via COX-2 from arachidonic acid, drives cancer progression by promoting tumor growth, angiogenesis, invasion, and metastasis through receptor-mediated signaling in tumors like colorectal cancer.
PGE2 acts via EP receptors to activate pathways such as β-catenin signaling and adaptation to the tumor microenvironment (Greenhough et al., 2009, 1188 citations). COX-2 overexpression correlates with PGE2 elevation in colorectal adenomas and adenocarcinomas (Eberhart et al., 1994, 2515 citations). NSAIDs inhibit COX-2 to reduce PGE2 and suppress these oncogenic effects (Sano et al., 1995, 1136 citations).
Why It Matters
PGE2 inhibition via NSAIDs like aspirin reduces colorectal cancer risk, as shown in epidemiological data linking COX-2 suppression to chemoprevention (Wang, 2005, 882 citations). In mouse models, host COX-2 modulates carcinoma growth through PGE2 paracrine signaling (Williams et al., 2000, 677 citations). Targeting PGE2 pathways supports therapies for inflammation-driven cancers, with PGE2 stimulating colon cancer growth via Gs-Axin-β-catenin axis (Castellone et al., 2005, 877 citations).
Key Research Challenges
Heterogeneity of EP Receptor Signaling
PGE2 signals through four EP receptors with context-dependent effects in different cancers, complicating targeted inhibition (Greenhough et al., 2009). Distinguishing autocrine vs paracrine roles requires advanced imaging (Ricciotti and FitzGerald, 2011). Over 3600 studies highlight variable receptor expression across tumor types.
COX-2/PGE2 Pathway Resistance
Tumors adapt to COX-2 inhibition via microenvironment changes, reducing NSAID efficacy (Greenhough et al., 2009). Host-tumor PGE2 crosstalk persists despite NSAIDs (Williams et al., 2000). Bindu et al. (2020, 1711 citations) note organ-specific toxicities limiting chronic use.
Quantifying PGE2 Oncogenic Contributions
Isolating PGE2 effects from other prostaglandins demands precise knockouts, as in COX-2 models (Williams et al., 2000). Measuring dynamic PGE2 levels in vivo remains technically challenging (Ricciotti and FitzGerald, 2011). Clinical translation from adenomas to metastases needs longitudinal data (Eberhart et al., 1994).
Essential Papers
Prostaglandins and Inflammation
Emanuela Ricciotti, Garret A. FitzGerald · 2011 · Arteriosclerosis Thrombosis and Vascular Biology · 3.6K citations
Prostaglandins are lipid autacoids derived from arachidonic acid. They both sustain homeostatic functions and mediate pathogenic mechanisms, including the inflammatory response. They are generated ...
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Charles E. Eberhart, R J Coffey, Radhika Aramandla et al. · 1994 · Gastroenterology · 2.5K citations
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Samik Bindu, Somnath Mazumder, Uday Bandyopadhyay · 2020 · Biochemical Pharmacology · 1.7K citations
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Alexander Greenhough, H Smartt, Alice E. Moore et al. · 2009 · Carcinogenesis · 1.2K citations
It is widely accepted that alterations to cyclooxygenase-2 (COX-2) expression and the abundance of its enzymatic product prostaglandin E(2) (PGE(2)) have key roles in influencing the development of...
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Hajime Sano, Yutaka Kawahito, Ronald L. Wilder et al. · 1995 · PubMed · 1.1K citations
Several studies indicate that nonsteroidal anti-inflammatory drugs including indomethacin, aspirin, sulindac, and piroxicam reduce the risk of colon cancer. Furthermore, nonsteroidal anti-inflammat...
PROSTAGLANDINS AND CANCER
Diandian Wang · 2005 · Gut · 882 citations
Chemoprevention has been considered as a possible approach for cancer prevention. A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over ...
Prostaglandin E <sub>2</sub> Promotes Colon Cancer Cell Growth Through a G <sub>s</sub> -Axin-ß-Catenin Signaling Axis
Maria Domenica Castellone, Hidemi Teramoto, Bart O. Williams et al. · 2005 · Science · 877 citations
How cyclooxygenase-2 (COX-2) and its proinflammatory metabolite prostaglandin E2 (PGE2) enhance colon cancer progression remains poorly understood. We show that PGE2 stimulates colon cancer cell gr...
Reading Guide
Foundational Papers
Start with Ricciotti and FitzGerald (2011, 3607 citations) for prostaglandin basics, then Eberhart et al. (1994, 2515 citations) for COX-2 in adenomas, Greenhough et al. (2009) for PGE2 hallmarks.
Recent Advances
Bindu et al. (2020, 1711 citations) covers NSAID toxicities; focus on adaptation mechanisms building on Greenhough et al. (2009).
Core Methods
COX-2 IHC and qPCR for expression (Sano et al., 1995; Eberhart et al., 1994); genetic knockouts for host effects (Williams et al., 2000); G-protein assays for signaling (Castellone et al., 2005).
How PapersFlow Helps You Research Prostaglandin E2 in Cancer Progression
Discover & Search
Research Agent uses searchPapers('Prostaglandin E2 cancer progression COX-2') to retrieve Greenhough et al. (2009), then citationGraph reveals 1188 forward citations linking PGE2 to hallmarks of cancer. exaSearch uncovers recent NSAID trials; findSimilarPapers expands to colorectal-specific PGE2 signaling from Ricciotti and FitzGerald (2011).
Analyze & Verify
Analysis Agent runs readPaperContent on Castellone et al. (2005) to extract Gs-Axin-β-catenin pathway details, then verifyResponse with CoVe cross-checks claims against Eberhart et al. (1994). runPythonAnalysis processes citation data with pandas to quantify COX-2 upregulation trends; GRADE assigns high evidence to NSAID chemoprevention (Wang, 2005).
Synthesize & Write
Synthesis Agent detects gaps in EP receptor specificity from Greenhough et al. (2009) vs Sano et al. (1995), flags contradictions in host-tumor PGE2 roles (Williams et al., 2000). Writing Agent uses latexEditText for review drafting, latexSyncCitations integrates 10 key papers, latexCompile generates PDF; exportMermaid visualizes COX-2/PGE2 signaling cascades.
Use Cases
"Extract PGE2 concentration data from colorectal cancer papers and plot COX-2 expression correlation."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted data from Eberhart 1994, Sano 1995) → matplotlib plot of expression vs progression stage.
"Draft LaTeX review on PGE2 inhibition strategies with citations."
Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure (PGE2 pathway), latexSyncCitations (Wang 2005, Greenhough 2009), latexCompile → camera-ready PDF section on NSAIDs.
"Find GitHub repos analyzing PGE2 signaling models from these papers."
Research Agent → paperExtractUrls (Castellone 2005) → paperFindGithubRepo → githubRepoInspect → Python simulation of β-catenin activation from PGE2 dose-response data.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'PGE2 colorectal cancer NSAIDs', structures report with COX-2/PGE2 timelines from Eberhart (1994) to Bindu (2020). DeepScan applies 7-step CoVe to verify PGE2 claims in Greenhough (2009), checkpoint-grading evidence. Theorizer generates hypotheses on EP4-targeted therapies from Ricciotti (2011) and Castellone (2005) signaling data.
Frequently Asked Questions
What defines PGE2's role in cancer progression?
PGE2, via COX-2, promotes proliferation, angiogenesis, and metastasis through EP receptors and β-catenin signaling (Greenhough et al., 2009; Castellone et al., 2005).
What are key methods to study PGE2 in cancer?
COX-2 knockout mice assess host contributions (Williams et al., 2000); qPCR measures expression in adenomas (Eberhart et al., 1994); EP agonists dissect signaling (Castellone et al., 2005).
What are landmark papers on this topic?
Eberhart et al. (1994, 2515 citations) showed COX-2 upregulation; Greenhough et al. (2009, 1188 citations) detailed hallmarks roles; Ricciotti and FitzGerald (2011, 3607 citations) overviewed prostaglandin inflammation.
What open problems exist?
Receptor-specific inhibitors face adaptation issues (Greenhough et al., 2009); quantifying paracrine PGE2 needs better models (Williams et al., 2000); NSAID toxicities limit translation (Bindu et al., 2020).
Research Inflammatory mediators and NSAID effects with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Prostaglandin E2 in Cancer Progression with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers